Immunohistochemical expression of p53, fibroblast growth factor-b, and transforming growth factor-alpha in feline vaccine-associated sarcomas.
Fifty feline sarcomas associated with vaccine-site injection were evaluated to determine the immunohistochemical expression of p53 protein, basic fibroblast growth factor (FGF-b), and transforming growth factor-alpha (TGF-alpha). Forty-one tumors (82%) were fibrosarcomas (FS), eight (16%) were malignant fibrous histiocytomas (MFH), and one (2%) was a chondrosarcoma (CS). Overexpression of p53 protein was observed in the nuclei of tumor cells in 28 (56%) sarcomas; FGF-b expression was found in the cytoplasm of tumor cells in 40 (80%) feline sarcomas, but the staining was more intense in the spindle-shaped cells of FS than in polygonal or round cells of MFH. The single CS faintly expressed FGF-b. The majority of feline vaccine-associated sarcomas (43 of 50, 86%) expressed moderate or intense staining for TGF-alpha in the cytoplasm of tumor cells. Heterogeneous immunolabeling for p53, FGF-b, and TGF-alpha was present in neoplastic, multinucleated giant cells. Intense expression of FGF-b was statistically associated with younger cats (P < 0.01) and with tumors with nodular growth patterns (P = 0.02). In addition, sarcomas negative for p53 protein expressed FGF-b more frequently than did p53-positive tumors (P = 0.04). The frequency of FGF-b immunostaining was significantly higher in sarcomas with intense expression of TGF-alpha (P = 0.05). Immunohistochemical detection of p53 protein, FGF-b, and TGF-alpha suggests that these growth-regulating proteins may play different roles in the development of sarcomas associated with vaccine sites.
Nieto
A
A
Departamento de Patología Animal II, Facultad de Veterinaria, Universidad Complutense de Madrid, 28040 Madrid, Spain.
Sánchez
M A
MA
Martínez
E
E
Rollán
E
E
D000818:Animals; D002371:Cat Diseases / Q000209:etiology* / Q000378:metabolism; D002415:Cats; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism*; D007150:Immunohistochemistry; D012509:Sarcoma / Q000209:etiology / Q000378:metabolism / Q000662:veterinary*; D016211:Transforming Growth Factor alpha / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary
D016211:Transforming Growth Factor alpha; D016159:Tumor Suppressor Protein p53; D016222:Fibroblast Growth Factor 2